CarrierAdvance

CarrierAdvance is an innovative genetic test that allows identification of couples at risk of transmitting the most common genetic diseases to their children, by detecting DNA mutations of which one or both parents may be unwitting carriers.

Each person is born with genetic characteristics that differentiate him/her from others and that make this person unique. While most of the differences in the DNA sequence between different people is harmless, some changes, kown as "mutations", can alter genomic functionality and make that person a carrier of a specific genetic disease, transmissible to their children.

In most cases, carriers of genetic diseases are healthy individuals and show no symptoms, have no known family history of the disease, and are unaware that they are at risk of passing this DNA "error" to their children.

If both partners of the couple carry mutations in the same gene with autosomal recessive inheritance, there will be an increased risk (25%) of conceiving a child with that specific disease. If a woman is a carrier of a X-linked disorder, 50% of male children will be at risk of having that specific genetic disease.

carrier screening test

INDICATION FOR TESTING

Carrier Advance is intended to be used as a family planning tool, allowing patients to be tested individually or with their reproductive partner for their risk of having children with various genetic conditions.

For patients who are pursuing pregnancy with assisted reproductive technologies.
Couples requiring gamete donation, in order to select the most appropriate donor for each recipient (i.e. a donor that doesn’t carry the same mutation as the member of the couple who will provide the gametes), minimizing the reproductive risk.
Anyone who wants to know if they are carrier of any condition included in the panel.
Individuals with a family history of a genetic disease, who are therefore at higher risk of being carriers for those diseases.

6 LEVELS OF SCREENING

Carrieradvance Essential

Essential

13 Genes
The 14 pathologies considered essential due to their prevalence in the population.

Carrieradvance Focus

Focus

30 Genes
30+ of the most common diseases in the population

Carrieradvance Standard

Standard

420 Genes
420 of the most common pathologies in the population, including those recommended by international medical societies

Carrieradvance Plus

Plus

925 Genes
1467 of the most common pathologies in the population, including those recommended by medical societies (ACOG and ACMG)

Carrieradvance Exome

Exome

4000+ Genes
Complete exome, 5000+ pathologies, for a comprehensive screening

Carrieradvance Exome Infertility

Exome Infertility

7000+ Genes
Comprehensive carrier screening, genetics of couple infertility, TESE prognosis in NOA, and predisposition to embryonic aneuploidy.

Discover

Exome Infertility

The most advanced level of CarrierAdvance, specifically designed for couples with reproductive difficulties who are planning a pregnancy through Assisted Reproductive Technology (ART).

Carrier Screening Esteso
Extended Carrier Screening

In-depth analysis of over 7,000 genes for the identification of carriers of transmissible genetic diseases.

Genetica dell'Infertilità di Coppia
Couple Infertility Genetics

Comprehensive genetic investigation of the molecular causes of male and female infertility.

Prognosi TESE in NOA
TESE Prognosis in NOA

Prognostic evaluation for Testicular Sperm Extraction in patients with Non-Obstructive Azoospermia.

Predisposizione ad Aneuploidie Embrionali
Predisposition to Embryonic Aneuploidies

Identification of the genetic predisposition to the development of chromosomal errors in embryos.

A GROUNDBREAKING TECHNOLOGY COUPLED WITH AN ADVANCED BIOINFORMATIC ANALYSIS TO DELIVER GREATER ACCURACY

CarrierAdvance state-of-the-art technological process

CarrierAdvance uses a state-of-the-art technological process, named Next Generation Sequencing (NGS). Unlike other carrier screening tests using targeted sequencing, CarrierAdvance is carried out performing full exon sequencing of all the genes included in the panel, which allows a more comprehensive assessment of each gene and related diseases.

4 easy steps

CarrierAdvance

Turnaround time:
Turnaround time 20 days

TEST RESULTS

Negative

No mutations identified: this test result indicates that not known or likely pathogenic mutations have been detected in the targeted genes screened. A single test cannot always detect all possible genetic changes. Hence, a negative test results do not completely rule out the the possibility of carrying a mutation located in a region of the genome not investigated by the test.

+

Positive

Identification of one or more mutations: this test result indicates that one or more mutations have been detected in the targeted genes screened, identifying the patient as a carrier. Mutations reported in a POSITIVE CarrierAdvance test may be classified under the following prognosis categories:
Known pathogenic: clinical relevant mutations causing well-established syndromes;
Likely pathogenic: variants that are likely clinical relevant and may cause well-established syndromes.
Classification follows the recommendations of the international reference guidelines. 1.

?

UNCERTAIN CLINICAL RESULT

Variants of uncertain clinical significance (VUS): this test result indicates that one or more variants of uncertain clinical significance have been detected in the targeted genes screened. These are variants with insufficient evidence available for unequivocal determination of clinical significance. VOUS will only be reported if both partners perform the test and one of them is found to be carrier of a known pathogenic mutation.

1Richards et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;17(5):405-423.

CarrierAdvance

Sample requested:

  • Peripheral blood

UN TEST ESEGUIBILE IN POCHI SEMPLICI PASSAGGI

Possibili esiti di

Negativo

Il test non ha individuato alcuna mutazione nei geni investigati. Tale risultato non esclude la possibilità di essere portatori di una mutazione localizzata in una regione del genoma non investigata dal test.

+

Positivo

Il test ha individuato una o più mutazioni a significato patologico noto in uno o più dei geni investigati. Tale risultato è compatibile con la condizione di portatore di una o più malattie genetiche. Il portatore di una malattia genetica recessiva è asintomatico.

?

Incerto

Il test ha individuato una o più varianti genetiche a significato clinico incerto in uno o più dei geni investigati. Si tratta di varianti non ancora note o caratterizzate dalla comunità medico-scientifica, che verranno refertate solo nei test eseguiti su entrambi i partners della coppia, nel caso in cui in uno dei partners dovesse essere stata riscontrata una mutazione a significato patologico noto.

CarrierAdvance

Tempi di refertazione:
20 giorni

WHY CHOOSE


Over 100.000
genetic tests/year
Test performed in Italy
(Rome or Milan)
20+ years experience in prenatal molecular diagnostics
Fast
TAT
Dedicated
R&D team
Laboratories with groundbreaking technologies and high quality standards
Personalized genetic counseling with genetic counselors experts in discussing genetic test results and familial risks
International
Partnership

WHY CHOOSE


Over 100.000 genetic tests/year
Test performed in Italy
(Rome or Milan)
20+ years experience
in prenatal molecular diagnostics
Fast TAT
3 days
Dedicated
R&D team
Laboratories with groundbreaking technologies and high quality standards
Personalized genetic counseling with genetic counselors experts in discussing genetic test results and familial risks
International
Partnership

Brochure

Download the CarrierAdvance and CarrierAdvance Exome Infertility brochure.

Brochure CarrierAdvance

CarrierAdvance

Download brochure
Brochure CarrierAdvance Exome Infertility

CarrierAdvance Exome Infertility

Download brochure

INFORMATION REQUEST FOR CARRIERADVANCE TEST

Fill out this form for a free consultation.
One of our professionals will contact you, free of charge and without obligation, to provide you with all the information you need.

I have read and accept Privacy Policy